NCT02500199 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02500199
Title	Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Recruitment	Unknown status
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Hengrui Therapeutics, Inc.
Indications	lung non-small cell carcinoma Her2-receptor positive breast cancer Advanced Solid Tumor stomach cancer
Therapies	Pyrotinib
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 10 of 10 entries

Facility	City	State	Zip	Country	Details
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	United States	Details
Florida Cancer Specialists	Sarasota	Florida	34232	United States	Details
Henry Ford Health System	Detroit	Michigan	48202	United States	Details
Massachusetts General Hospital	Boston	Massachusetts	02114	United States	Details
Memorial Sloan Kettering Cancer Center	New York	New York	10065	United States	Details
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	United States	Details
Tennessee Oncology	Nashville	Tennessee	37203	United States	Details
UC Davis Comprehensive Cancer Center	Sacramento	California	95817	United States	Details
University of California, Irvine School of Medicine	Orange	California	92868	United States	Details
Washington University	Saint Louis	Missouri	63110	United States	Details

Showing 1 to 10 of 10 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT02500199Clinical Trial Detail